InflaRx to Report Second Quarter 2026 Results on August 6, 2026

InflaRx (Nasdaq: IFRX) announced it will report its second quarter 2026 financial and operating results on August 6, 2026, before the U.S. market opens.

Rhea-AI Summary

InflaRx (Nasdaq: IFRX) announced it will report its second quarter 2026 financial and operating results on August 6, 2026, before the U.S. market opens. The company does not plan to hold a conference call in connection with this release.

InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement factor C5a and its receptor C5aR. Its lead oral small-molecule program, izicopan, is being developed for ANCA-associated vasculitis and additional renal diseases, while vilobelimab, an intravenously delivered monoclonal antibody, has shown clinical activity and tolerability in multiple studies.

Argus Jul 30 session 4 alerts

+4.24% close to close 0.8x rel. volume Open Argus

Details

Market reaction after 2Q26 earnings report: IFRX +4.24% in the Jul 30 session

-4.7% Trough Tracked

$261.75M Market Cap

In the Jul 30 session, IFRX gained 4.24%, reflecting a moderate positive market reaction. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The two prior earnings-date events moved 1.45% and 1.96% over 24 hours, giving this recurring schedu...

Analysis

The two prior earnings-date events moved 1.45% and 1.96% over 24 hours, giving this recurring scheduling format a documented comparison. Short positioning is an additional risk factor; the August 6 release remains the next factual checkpoint.

Key Figures

Reporting Date: August 6, 2026 Izicopan Study Stages: Phase 1 and Phase 2a Company Founded: 2007

Reporting Date

August 6, 2026

Second quarter 2026 results, before market opens

Izicopan Study Stages

Phase 1 and Phase 2a

Prior clinical studies

Company Founded

2007

InflaRx N.V.

Previous Earnings date Reports

2 past events · Latest: May 01

Same Type 2 events

1. May 01

   First-quarter results date

   24h Move

   +1.4%

   Announced first-quarter results release before market open without a conference call

2. Mar 12

   Full-year results date

   24h Move

   +2.0%

   Announced fourth-quarter and full-year results release without a conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pk/pd, c5ar, monoclonal antibody, complement system

4 terms

pk/pd medical

"which has shown promising PK/PD characteristics as well as therapeutic potential"

PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.

c5ar medical

"its proprietary anti-C5a and anti-C5aR technologies"

C5aR is a protein on the surface of immune cells that senses and responds to a small immune signaling molecule called C5a; when activated it acts like a doorbell that calls immune cells and ramps up inflammation. It matters to investors because drugs that block or modulate this receptor can reduce harmful inflammation in diseases, so clinical trial results, approvals, or setbacks for C5aR-targeting therapies can materially affect a biotech’s value and market prospects.

monoclonal antibody medical

"a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

complement system medical

"anti-inflammatory therapeutics by targeting the complement system"

The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned.

About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will InflaRx (Nasdaq: IFRX) report its Q2 2026 earnings?

InflaRx will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. According to InflaRx, the announcement will be released without an accompanying earnings conference call.

Will InflaRx (IFRX) hold a conference call for its Q2 2026 results?

InflaRx does not plan to hold a conference call for its second quarter 2026 results. According to InflaRx, the company will only issue a financial and operating results release before the market opens on August 6, 2026.

What is InflaRx’s lead program mentioned with the Q2 2026 results timing?

InflaRx’s lead program is izicopan, an orally administered small molecule inhibiting C5a-induced signaling via C5aR. According to InflaRx, izicopan has shown promising Phase 1 and Phase 2a data and is being developed for ANCA-associated vasculitis and other renal diseases.

What does InflaRx (IFRX) develop with its anti-C5a and anti-C5aR technologies?

InflaRx develops highly potent and specific inhibitors of the complement factor C5a and its receptor C5aR. According to InflaRx, these anti-inflammatory therapeutics target C5a, a powerful inflammatory mediator involved in many inflammatory diseases.

What is vilobelimab in InflaRx’s pipeline as of the Q2 2026 update?

Vilobelimab is a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody developed by InflaRx. According to InflaRx, vilobelimab selectively binds free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

Where is InflaRx headquartered and where are its main offices located?

InflaRx was founded in 2007 and is based in Germany, with offices in Jena and Munich. According to InflaRx, the group also has a subsidiary presence in Ann Arbor, Michigan, USA, through InflaRx Pharmaceuticals.